Comparing the diagnostic efficacy of [99mTc]Tc-HYNIC-PSMA-11 SPECT/CT scanning after 75 minutes and 4 hours of radiotracer injection in men with prostate cancer

Document Type : Original Article

Authors

1 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Pharmaceutical Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Clinical Research Development Unit, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Introduction: Prostate-Specific Membrane Antigen (PSMA) is overexpressed in primary and metastatic prostate carcinoma (PCa) and could be targeted by a [99mTc]Tc-HYNIC-PSMA-11 scan for detection of metastases. Despite extensive studies, data on the most appropriate interval between radiopharmaceutical injection and image acquisition is scarce. We compared the metastasis detection rates of the [99mTc]Tc-HYNIC-PSMA-11 scan between 75-minute and 4-hour intervals of radiopharmaceutical injection.
Methods: From May 2021 to May 2022, we studied 30 consenting men with pathologically confirmed PCa who were referred to our department requesting  a PSMA scan for primary staging, biochemical recurrence, pre-177Lu-PSMA therapy, or surveillance. 75-minute and 4-hour [99mTc]Tc-HYNIC-PSMA-11 SPECT/CT scan performed following injection of the radiopharmaceutical. The corresponding  metastasis detection rates were evaluated in 75-minute and 4-hour intervals.
Results: The mean age of patients was 68.43±9.61 years, with a median PSA of 4.19 ng/ml and a median Gleason Score of 8. Nine cases had negative [99mTc]Tc-HYNIC-PSMA-11 scans, while 21 had positive scans (8 cases with bone, 2 with lung, 4 with lymph node, and 7 with multiple organ metastases). All metastases were detected in both checkpoints, except for one patient, where 75-minute images detected three pelvic metastatic lymph nodes, while four were seen in the 4-hour scan. This small missed right external iliac lymph node did not change the patient’s management.
Conclusion: We found no significant difference in the detection rate of metastatic lesions in 75-minute and 4-hour time intervals. These findings could help to decrease  waiting time and  by more efficient scheduling improves patient’s satisfaction at nuclear medicine departments.

Keywords

Main Subjects

References

  1. SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/prost.html.
  2. American Cancer Society. Cancer Statistics Center 2022 [cited 2022 Oct 23]. Available from: https://cancerstatisticscenter.cancer.org/#!/.
  3. Kabunda J, Gabela L, Kalinda C, Aldous C, Pillay V, Nyakale N. Comparing 99mTc-PSMA to 99mTc-MDP in prostate cancer staging of the skeletal system. Clin Nucl Med. 2021 Jul 1;46(7):562-568.
  4. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009 Jun;15(2):167-72.
  5. Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C. Intraindividual comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in patients with osseous metastasized prostate cancer. J Nucl Med. 2018 Sep;59(9):1373-9.
  6. Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP. 18F-Labeled, PSMA-Targeted Radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020 Jan 1;10(1):1-16.
  7. Peng Y, Wang T, Li X, Zuo C. Study on the best acquisition time of99mTc-PSMA SPECT for the prostate cancer imaging. J Nucl Med. 2020;61(supplement 1):3032.
  8. Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R. Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2086-95.
  9. Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, Bannas P, Knipper S, Eiber M, Maurer T. Delayed imaging improves lesion detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in recurrent prostate cancer. J Nucl Med. 2023 Jul;64(7):1036-42.
  10. Albalooshi B, Al Sharhan M, Bagheri F, Miyanath S, Ray B, Muhasin M, Zakavi SR. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol. 2020 Winter;8(1):1-7.
  11. Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, Eftekhari M, Beiki D. 99mTc-PSMA SPECT/CT versus 68Ga-PSMA PET/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2021 Feb 1;46(2):e68-74.

Files

Share

How to cite

Statistics